Abeona Therapeutics Q3 net loss narrows 76% quarter-on-quarter to $4.8 million

• Abeona Therapeutics’ third-quarter 2026 net loss narrowed 76% from the second quarter to $4.8 million.
• Net ZEVASKYN revenue rose 18% from the second quarter to $13.5 million.
• Six ZEVASKYN treatments were completed during the quarter, bringing the total since launch to 15.
• Abeona acquired Phase 3-ready EoE candidate APT-1011 from Ellodi Pharmaceuticals and announced a $30 million PIPE financing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeona Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611090635PRIMZONEFULLFEED9872994) on November 09, 2026, and is solely responsible for the information contained therein.